0Y3M Stock Overview
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Prothena Corporation plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$50.66 |
| 52 Week High | US$65.23 |
| 52 Week Low | US$25.27 |
| Beta | 0.50 |
| 1 Month Change | -10.72% |
| 3 Month Change | -14.38% |
| 1 Year Change | 44.78% |
| 3 Year Change | n/a |
| 5 Year Change | 13.66% |
| Change since IPO | 15.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Y3M | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -9.9% | -2.6% | -1.1% |
| 1Y | 44.8% | -23.7% | -3.9% |
Return vs Industry: 0Y3M exceeded the UK Biotechs industry which returned -23.2% over the past year.
Return vs Market: 0Y3M exceeded the UK Market which returned -2.5% over the past year.
Price Volatility
| 0Y3M volatility | |
|---|---|
| 0Y3M Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0Y3M is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: Insufficient data to determine 0Y3M's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 82 | Gene Kinney | https://www.prothena.com |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer’s disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease.
Prothena Corporation plc Fundamentals Summary
| 0Y3M fundamental statistics | |
|---|---|
| Market Cap | US$2.84b |
| Earnings (TTM) | -US$156.48m |
| Revenue (TTM) | US$5.15m |
551.9x
P/S Ratio-18.2x
P/E RatioIs 0Y3M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Y3M income statement (TTM) | |
|---|---|
| Revenue | US$5.15m |
| Cost of Revenue | US$120.75m |
| Gross Profit | -US$115.59m |
| Other Expenses | US$40.88m |
| Earnings | -US$156.48m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.03 |
| Gross Margin | -2,242.82% |
| Net Profit Margin | -3,036.03% |
| Debt/Equity Ratio | 0% |
How did 0Y3M perform over the long term?
See historical performance and comparison